Cohance Lifesciences shares gained more than 2% intraday on Thursday following the company's regulatory disclosure, with the stock trading at ₹438.5 on NSE around 10:42 am, up from its previous close of ₹429.45. According to latest reports, the market took comfort from the absence of data integrity observations in the USFDA inspection results. The pharma stock has fallen around 53% over the past year, reflecting concerns over business performance and regulatory overhangs, but today's gains pushed the weekly gains to around 3%. The stock is currently trading at a price-to-earnings multiple of 280.7 times, with its market cap standing at ₹16,787.05 crore as of the last trading session.
Cohance Lifesciences received a Form 483 containing five observations from the United States Food and Drug Administration (USFDA) following an inspection of its manufacturing facility in Hyderabad. According to reports from CNBC TV18, the USFDA conducted an inspection of the company's manufacturing facility located at Pashamylaram in Hyderabad between July 27 and August 5, 2026. A Form 483 is issued by the USFDA when inspectors identify potential areas of concern during a facility inspection, allowing the company to review issues and submit a response including corrective and preventive actions. Cohance stated that none of the observations issued by the regulator relate to data integrity issues, which is a key area of focus in pharmaceutical manufacturing compliance. The company emphasized that the observations are addressable and that it will continue to engage with the USFDA to ensure timely and effective resolution.
Cohance Lifesciences reported a consolidated net loss of ₹24.1 crore in Q1 FY27, marking a significant deterioration from the profit of ₹48.9 crore in the year-ago period. The company's revenue from operations fell 23.1% year-on-year to ₹422 crore in the June quarter from ₹549 crore a year ago. According to latest reports, EBITDA declined sharply by 99% to ₹1.2 crore from ₹112 crore, resulting in a dramatic contraction of EBITDA margin to 0.3% from 20.4% in the previous year. The weakness extended across all business divisions, with Macquarie attributing the revenue contraction mainly to the Pharma CDMO segment, while Jefferies noted sales declined across all three business divisions. The numbers point to a sharp deterioration in profitability, with margins coming under severe pressure amid lower revenue.
Despite the disappointing financial performance, investors focused on the company's regulatory disclosure, with the absence of data integrity observations being viewed positively by investors. As reported by CNBC TV18, Cohance said it is assessing the observations and will submit a comprehensive response, including corrective and preventive actions (CAPAs), within the prescribed timeline. The company added that it believes the observations are addressable and will continue working closely with the regulator for their resolution. While the company still needs to address the five observations, the disclosure reduces the risk of a more adverse regulatory outcome and may have helped offset concerns arising from the weak quarterly results. The regulatory update appears to be the key reason why Cohance Lifesciences shares traded higher despite reporting one of its weakest quarterly performances in recent years.
ICICI Securities recommended a reduce rating on Cohance Lifesciences with a target price of ₹365 in its research report dated August 06, 2026, down from its previous target of ₹415. According to the latest report, ICICI Securities cut FY27/28E earnings by ~38%/5% to factor in slower growth and lower margins. The brokerage noted that Q1FY27 performance was sub-par, marred by the lumpy nature of the CDMO business and a high-cost base coupled with mounting losses of NJ Bio. However, management remains hopeful for sequential improvement in Q2FY27, with recovery in growth and EBITDA margins expected in H2FY27. The brokerage expects steady flow of commercial orders for CDMO projects, timely execution of order book at Sapala, regulatory compliance and new orders inflow at NJ Bio could help a sustained recovery in FY28.
